Navigation Links
Drug Found To Reduce The Transmission Of Herpes

Researchers say transmission of genital herpes to others is the chief concern in patients with the virus. However a new study shows //the drug valacyclovir may significantly reduce the spread of the genital herpes virus.
Researchers studied more than 1,400 heterosexual couples. In each case, one partner was diagnosed with type 2 herpes and the other was susceptible to the virus. Type 2 herpes causes a chronic genital viral infection and is often contagious. Participants with herpes were given either 500 milligrams of valacyclovir once a day or a placebo for eight months. Susceptible partners were evaluated monthly for symptoms of the virus. Both partners were counseled on safe sex and were offered condoms at each visit.

Results of the study show only four out of 743 of the susceptible partners who were given the drug developed clinically symptomatic herpes. However, 16 out of 741 participants who were given a placebo developed the virus. Overall, type 2 herpes was observed in 14 of the susceptible partners who received valacyclovir and 27 of the partners who received a placebo.

Researchers thus conclude that their study demonstrates that oral valacyclovir taken by immunocompetent persons with recurrent genital HSV-2 infection significantly reduces the rates of HSV reactivation, subclinical shedding, and transmission of genital herpes to a susceptible partner.
'"/>




Page: 1

Related medicine news :

1. Fluoride Found Effective in Osteoporosis
2. Implantable Contact Lens Found Safe and Effective
3. Cancer hazard Found With Animal-Based Nutrients
4. Processed Meat, Diabetes connection Found
5. Night Time Aspirin Regimen Found to Reduce Blood Pressure
6. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
7. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Common Cold Found to Fight Cancer
10. Circumcision Found To Prevent HIV Spread
11. Methamphetamine Users Found To Suffer From Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... ... American Farmer proudly announces the participation of Pure Line Seeds, Inc (Pure Line ... fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , Founded in ... demand grew, the small company located in Moscow, Idaho extended its sales from Northern ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance Agency, a ... northern Virginia and DC, is announcing a cooperative charity event in conjunction with ... other disorders that lead to memory impairment. , The Insight Memory Care Center ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized autonomous ... Ethereum blockchain, has released their technical specifications . , 2017 has seen an ... systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder ...
(Date:6/27/2017)... ... 2017 , ... A January 18th article on medGadget reports that ... by the year 2024 according to a new report. The article also notes that ... titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and ... offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: